Mir-320e and colorectal cancer

Abstract

Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients.

1 - 40 . (canceled) 
     
     
         41 . A method for treating a patient with colorectal cancer comprising administering a treatment to the patient that inhibits the expression of miR-320e, wherein a sample from the patient is determined to have an increased expression level in a gene encoding miR-320e compared to a control or reference expression level for the gene. 
     
     
         42 - 51 . (canceled) 
     
     
         52 . The method of  claim 41 , wherein the sample from the patient comprises a tissue sample, a whole blood sample, a urine sample, a saliva sample, a serum sample or a fecal sample. 
     
     
         53 . The method of  claim 41 , wherein the sample is a tissue sample. 
     
     
         54 . The method of  claim 41 , wherein the sample is a rectum sample, a colon sample or a cecum sample. 
     
     
         55 . The method of  claim 54 , wherein the sample is a rectum sample. 
     
     
         56 . The method of  claim 41 , wherein the sample is a fresh sample, frozen sample, preserved sample, formalin-fixed, paraffin-embedded (FFPE) sample, or a fine needle aspirate. 
     
     
         57 . The method of  claim 41 , wherein the cancer is stage II or III colorectal cancer. 
     
     
         58 . The method of  claim 41 , wherein the cancer is stage IV colorectal cancer. 
     
     
         59 . A method of detecting the expression level of miR-320e in a human subject diagnosed with colorectal cancer and selecting a treatment for a human subject diagnosed with colorectal cancer, the method comprising:
 a.) assaying nucleic acids obtained from a biological sample from the human subject to determine a first expression level of miR-320e in the biological sample from the human subject; and   b.) comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of recurrent colorectal cancer; or
 comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of non-recurrent colorectal cancer. 
   
     
     
         60 . The method of  claim 59 , wherein the sample from the patient comprises a tissue sample, a whole blood sample, a urine sample, a saliva sample, a serum sample or a fecal sample. 
     
     
         61 . The method of  claim 59 , wherein the biological sample from the human subject comprises a tissue sample. 
     
     
         62 . The method of  claim 59 , wherein the biological sample from the human subject comprises a rectum sample, a colon sample or a cecum sample. 
     
     
         63 . The method of  claim 59 , wherein the biological sample from the human subject comprises is a rectum sample. 
     
     
         64 . The method of  claim 59 , wherein the biological sample from the human subject comprises a fresh sample, frozen sample, preserved sample, formalin-fixed, paraffin-embedded (FFPE) sample, or a fine needle aspirate. 
     
     
         65 . The method of  claim 59 , wherein assaying nucleic acids comprises the use of a microarray, PCR, digital PCR, dd PCR (digital droplet PCR), nCounter, BEAMing (Beads, Emulsions, Amplifications, and Magnetics), ARMS (Amplification Refractory Mutation Systems), RNA-Seq, TAm-Seg (Tagged-Amplicon deep sequencing), PAP (Pyrophosphorolysis-activation polymerization), RT-PCR, in situ hybridization, northern hybridization, hybridization protection assay (HPA), branched DNA (bDNA) assay, rolling circle amplification (RCA), single molecule hybridization detection, Invader assay, and/or Bridge Litigation Assay, next generation RNA sequencing, or a combination thereof. 
     
     
         66 . The method of  claim 59 , wherein the method comprises comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of recurrent colorectal cancer. 
     
     
         67 . The method of  claim 59 , wherein the method comprises comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of non-recurrent colorectal cancer. 
     
     
         68 . The method of  claim 66 , wherein the first expression level of miR-320e in the biological sample from the human subject is determined to be decreased compared to the reference level of expression. 
     
     
         69 . The method of  claim 67 , wherein the first expression level of miR-320e in the biological sample from the human subject is determined to be not significantly different than the reference level of expression. 
     
     
         70 . The method of  claim 59 , wherein the method further comprises isolating nucleic acids from a biological sample from the patient.